Journal of Medicinal Chemistry · 2020 · 43 citations · 22 references
PharmacyMedicinal ChemistryOncologyApoptosisDrug DesignDrug DiscoveryApoptosis PharmacologyMitotic InhibitorsAnti-apoptotic AgentsAnticancer ActivityBiomolecular Binding AffinityCancer Cell Proliferation InhibitionCell Cycle InhibitionCell Cycle InhibitorsMicrotubule Network OrganizationTubulin Polymerization Inhibitors
Apcin is one of the few compounds that have been previously reported as a Cdc20 specific inhibitor, although Cdc20 is a very promising drug target. We reported here the design, synthesis, and biological evaluations of 2,2,2-trichloro-1-aryl carbamate derivatives as Cdc20 inhibitors. Among these derivatives, compound 9f was much more efficient than the positive compound apcin in inhibiting cancer cell growth, but it had approximately the same binding affinity with apcin in SPR assays. It is possible that another mechanism of action might exist. Further evidence demonstrated that compound 9f also inhibited tubulin polymerization, disorganized the microtubule network, and blocked the cell cycle at the M phase with changes in the expression of cyclins. Thus, it induced apoptosis through the activation of caspase-3 and PARP. In addition, compound 9f inhibited cell migration and invasion in a concentration-dependent manner. These results provide guidance for developing the current series as potential new anticancer therapeutics.
22
Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Katharine L. Sackton, Nevena Dimova, Xing Zeng et al. · Nature · 2014 · 263 citations
Cdc20 and securin overexpression predict short-term breast cancer survival
Henna Karra, Heli Repo, Ilmari Ahonen et al. · British Journal of Cancer · 2014 · 171 citations · Full text
CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer
Wen-jing Wu, Kai-shun Hu, De‐Shen Wang et al. · Journal of Translational Medicine · 2013 · 145 citations · Full text